ZENAS BIOPHARMA- CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF DEC 31 TO FUND OPERATING EXPENSES & CAPEX REQUIREMENTS INTO Q4 2026
Source text: ID:nGNE7m1MRZ
Further company coverage: ZBIO.O
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.